Pharmaceutical

ChromaDex wins orphan designation for rare ataxia drug

The company will be filing an IND for nicotinamide riboside chloride (NRC), which has received both orphan and rare pediatric designations.

Jun 8, 2024 - 04:00
ChromaDex wins orphan designation for rare ataxia drug
The company will be filing an IND for nicotinamide riboside chloride (NRC), which has received both orphan and rare pediatric designations.
Read the original article

Tags:

Previous Article

ASCO24: Another win for Opdivo/Yervoy in first-line HCC despite uncertainties

Next Article

FDA admonishes Jiangsu Hengrui’s manufacturing site following inspection

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

In historic decision, FDA approves a CRISPR-based medicine for treatment of sickle cell disease

In historic decision, FDA approves a CRISPR-based medic...

Dec 9, 2023

STAT+: Microsoft strikes partnership with Duke Health to advance AI in medicine

STAT+: Microsoft strikes partnership with Duke Health t...

Aug 1, 2023

Astellas invests $50m in Poseida’s CAR-T cell therapy

Astellas invests $50m in Poseida’s CAR-T cell therapy

Aug 8, 2023